June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Controlled degradation and protein release from an injectable hydrogel in the posterior eye
Author Affiliations & Notes
  • Chi Ming Laurence Lau
    The Hong Kong University of Science and Technology Shenzhen Research Institute, Shenzhen, China
    The Hong Kong University of Science and Technology, Hong Kong, Hong Kong
  • Yu Yu
    The Hong Kong University of Science and Technology, Hong Kong, Hong Kong
    Pleryon Therapeutics, Shenzhen, China
  • Xiaonan HUANG
    The Hong Kong University of Science and Technology Shenzhen Research Institute, Shenzhen, China
    The Hong Kong University of Science and Technology, Hong Kong, Hong Kong
  • Ying Chau
    The Hong Kong University of Science and Technology, Hong Kong, Hong Kong
    Pleryon Therapeutics, Shenzhen, China
  • Footnotes
    Commercial Relationships   Chi Ming Laurence Lau, Pleryon Therapeutics (P); Yu Yu, Pleryon Therapeutics (I), Pleryon Therapeutics (P); Xiaonan HUANG, None; Ying Chau, Pleryon Therapeutics (P), Pleryon Therapeutics (C), Pleryon Therapeutics (I)
  • Footnotes
    Support  JCY20170818114038319
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 2891. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Chi Ming Laurence Lau, Yu Yu, Xiaonan HUANG, Ying Chau; Controlled degradation and protein release from an injectable hydrogel in the posterior eye. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2891.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : This study aims to investigate the in vitro and in vivo sustained delivery of antibody from an injectable, hydrolysable, polysaccharide-based in situ hydrogel designed for long-term protein release.

Methods : The hydrogel was made by mixing the two polymer solution precursors, namely the vinyl sulfone (-VS) and the thiol (-SH) modified polysaccharides at physiological condition. Model IgG proteins were mixed with polymer precursor before crosslinking and were encapsulated after gel formation. The protein release rate was controlled by the hydrogel mesh size. Ester-based linkers of controllable hydrolysis rate were embedded in the polymer network so that the hydrogels were hydrolytic at physiological environment. The IgG encapsulated hydrogels were incubated in PBS (pH7.4) at 37oC in vitro to measure the in vitro degradation and release. Bevacizumab-encapsulated hydrogel was injected in rabbit vitreous, and the aqueous humor were sampled periodically to measure the pharmacokinetics of hydrogel formulation in the eye.

Results : The degradation of hydrogel and the release of protein was controlled to be at least 3 months in vitro and in vivo.

Conclusions : Hydrolytic hydrogel can be a suitable platform for the controlled release of protein therapeutics in the eye.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×